Payment overview · 2025
General Payments
$518.17
27 reported records · 15 companies
Healthcare provider profile · identity verified
Justin Elliot Fields, MD
Allopathic & Osteopathic Physicians|Internal Medicine · NORMAN, OK · NPI 1003013723
Verified facts
What the public records show
CMS Open Payments records show Justin Elliot Fields, MD received $518.17 in general payments during 2025 across 27 reported records.
Sumitomo Pharma America, Inc. accounted for 18.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Jardiance, Mounjaro, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $96.90 | 18.7% | 4 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $63.37 | 12.2% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $50.67 | 9.8% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $44.47 | 8.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $34.02 | 6.6% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $29.76 | 5.7% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $29.50 | 5.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $27.72 | 5.3% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $25.45 | 4.9% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $25.30 | 4.9% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $21.94 | 4.2% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $20.43 | 3.9% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $18.46 | 3.6% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $15.48 | 3.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.70 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $518.17 | 27 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $96.90 | 4 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $63.37 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $50.67 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $44.47 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $44.47 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $34.02 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $29.76 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $29.50 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $29.50 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $27.72 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $27.72 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $25.45 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $25.30 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $21.94 | 1 | 2025 |
Source payment records
|
|||||
| TERIPARATIDE Normalized: teriparatide |
Drug | Almatica Pharma LLC | $20.43 | 1 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $18.46 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $18.46 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $18.46 | 1 | 2025 |
Source payment records
|
|||||
| MENQUADFI Normalized: menquadfi |
Biological | SANOFI PASTEUR INC. | $18.46 | 1 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $15.48 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.03 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 54 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 64 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
54 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
54 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
64 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
78 | 23 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
80 | 22 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 578 | 164 |
| Levothyroxine Sodium | Levothyroxine Sodium | 308 | 85 |
| Amlodipine Besylate | Amlodipine Besylate | 262 | 72 |
| Losartan Potassium | Losartan Potassium | 252 | 71 |
| Omeprazole | Omeprazole | 212 | 59 |
| Lisinopril | Lisinopril | 210 | 57 |
| Metformin Hcl | Metformin Hcl | 177 | 50 |
| Gabapentin | Gabapentin | 153 | 51 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 144 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 130 | 36 |
| Pravastatin Sodium | Pravastatin Sodium | 129 | 40 |
| Sertraline Hcl | Sertraline Hcl | 129 | 38 |
| Simvastatin | Simvastatin | 128 | 37 |
| Trazodone Hcl | Trazodone Hcl | 125 | 48 |
| Escitalopram Oxalate | Escitalopram Oxalate | 118 | 28 |
| Potassium Chloride | Potassium Chloride | 117 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 116 | 35 |
| Meloxicam | Meloxicam | 115 | 36 |
| Pantoprazole Sodium | Pantoprazole Sodium | 115 | 36 |
| Tizanidine Hcl | Tizanidine Hcl | 113 | 32 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 107 | 38 |
| Furosemide | Furosemide | 104 | 33 |
| Alprazolam | Alprazolam | 102 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 95 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 91 | 33 |
| Alendronate Sodium | Alendronate Sodium | 89 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 86 | 29 |
| Eliquis | Apixaban | 80 | 22 |
| Ozempic | Semaglutide | 78 | 23 |
| Montelukast Sodium | Montelukast Sodium | 75 | 23 |
| Famotidine | Famotidine | 72 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 68 | 20 |
| Carvedilol | Carvedilol | 67 | 16 |
| Celecoxib | Celecoxib | 67 | 21 |
| Mounjaro | Tirzepatide | 64 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 56 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 55 | 15 |
| Jardiance | Empagliflozin | 54 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 53 | 19 |
| Methylprednisolone | Methylprednisolone | 51 | 41 |
| Allopurinol | Allopurinol | 48 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 48 | 13 |
| Metformin Hcl Er | Metformin Hcl | 48 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 48 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 48 | 17 |
| Finasteride | Finasteride | 47 | 13 |
| Bupropion Xl | Bupropion Hcl | 46 | 15 |
| Ondansetron Odt | Ondansetron | 46 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 46 | 12 |
| Azelastine Hcl | Azelastine Hcl | 44 | 16 |
| Ezetimibe | Ezetimibe | 43 | 13 |
| Pregabalin | Pregabalin | 42 | 14 |
| Atenolol | Atenolol | 39 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 39 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 39 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 37 | suppressed |
| Clonazepam | Clonazepam | 36 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 35 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 35 | 12 |
| Repatha Sureclick | Evolocumab | 34 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 32 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 31 | suppressed |
| Glipizide | Glipizide | 30 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | 11 |
| Prednisone | Prednisone | 29 | 16 |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Myrbetriq | Mirabegron | 28 | suppressed |
| Glimepiride | Glimepiride | 27 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Lorazepam | Lorazepam | 27 | 12 |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 15 |
| Propranolol Hcl Er | Propranolol Hcl | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | suppressed |
| Ibuprofen | Ibuprofen | 24 | 11 |
| Valsartan | Valsartan | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Torsemide | Torsemide | 21 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Olanzapine | Olanzapine | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Temazepam | Temazepam | 19 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 18 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 14 |
| Cefdinir | Cefdinir | 15 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Wegovy | Semaglutide | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Konvomep | Omeprazole/Sodium Bicarbonate | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Dexmethylphenidate Hcl Er | Dexmethylphenidate Hcl | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Endocet | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Oxycontin | Oxycodone Hcl | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $518.17 · 27 records | Sumitomo Pharma America, Inc. | AREXVY, BEYFORTUS, Dexcom G6 Transmitter, FANAPT, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, GEMTESA, INSPIRE, JARDIANCE, MENQUADFI, MOUNJARO, NURTEC ODT, OTEZLA, QULIPTA, REPATHA, SHINGRIX, TERIPARATIDE, UBRELVY, UNITHROID, WATCHMAN Access System, Wegovy, ZAVZPRET, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error